key: cord-0871869-6dfhqckr
authors: El-Sharkawy, Farah; Tang, Chi Ngong; Fitzgerald, Ayannah S.; Khatib, Layla A.; Graham-Wooten, Jevon; Glaser, Laurel; Collman, Ronald G.; Van Deerlin, Vivianna M.; Herlihy, Sarah E.
title: Saliva vs upper respiratory swabs: Equivalent for SARS-CoV-2 university screening while saliva positivity is prolonged post-symptom onset in COVID-19 hospitalized patients
date: 2022-04-27
journal: J Mol Diagn
DOI: 10.1016/j.jmoldx.2022.03.012
sha: ab554f40319311a870697294aa17b70b936e2622
doc_id: 871869
cord_uid: 6dfhqckr

Reopening of schools and workplaces during the ongoing COVID-19 pandemic requires affordable and convenient population-wide screening methods. While upper respiratory swab is considered the preferable specimen for testing, saliva offers several advantages such as easier collection and lower cost. In this study, we compared the performance of saliva with upper respiratory swab for SARS-CoV-2 detection. Paired saliva and anterior nares (AN) specimens were collected from a largely asymptomatic cohort of students, faculty, and staff from the University of Pennsylvania. Paired saliva and combined nasopharyngeal/oropharyngeal (NP/OP) specimens were also collected from hospitalized patients with symptomatic COVID-19 disease following confirmatory testing. All study samples were tested by real-time PCR in the Hospital of the University of Pennsylvania. In the university cohort, positivity rates were 37/2500 for saliva (sensitivity 86.1%) and 36/2500 for AN (sensitivity 83.7%), with an overall agreement of 99.6%. In the hospital study cohort, positivity rates were 35/49 for saliva (sensitivity 89.3%) and 28/49 for NP/OP (sensitivity 75.8%), with an overall agreement of 75.6%. A larger proportion of saliva than NP/OP samples tested positive after 4 days of symptom onset in hospitalized patients. Our results show that saliva has an acceptable sensitivity and is comparable to upper respiratory swab, supporting the use of saliva for SARS-CoV-2 detection in both symptomatic and asymptomatic populations.

In early 2020 as the COVID-19 pandemic spread rampantly across the world, mitigation efforts such as 20 stay-at-home orders were put in place to halt the progression of the virus. As schools and workplaces 21 began to reopen in many parts of the world during the summer of 2020, affordable and convenient 22 population-wide screening methods became ever more necessary. 1 University populations were of 23 specific concern with a high concentration of people living and studying in close quarters and those 24 people being active in the surrounding communities. Successful strategies to prevent infection at 25 universities included a well-designed plan for screening, contract tracing, isolation, and compliance with 26 policies. 2-4 A quick, yet robust method for collection and testing was necessary to meet the optimal 27 screening strategy. 28

While upper respiratory swabs (nasopharyngeal [NP] , oropharyngeal [OP] , mid-turbinate [MT] , and 29 anterior nares [AN] ) have been considered the preferable specimens for testing, several factors such as 30 supply shortage, need for trained personnel, technical difficulties and variability with specimen 31 collection, patient discomfort, and risk of exposure to health-care workers remain a limitation for 32 scalability. 1 Many studies have assessed the performance of saliva as an alternative specimen due to its 33 ease of collection and low cost. Because of the non-invasiveness and simplicity of saliva collection, 34 patients can self-collect either at a collection site or at home with minimal risk. Unlike swab specimen 35 collection, saliva can be collected in a sterile, nuclease-free tube and be stable at room temperature for 36 extended periods without stabilizing additives. 5, 6 In addition, studies have shown that saliva is a good 37 biological fluid for testing because of contact with the oral mucosa and salivary glands, which have high 38 expression of the ACE2 receptor that binds SARS-CoV-2. 7 39 6 transported via courier to the testing laboratory at the Hospital of the University of Pennsylvania (HUP) 64 and tested within 48 hours or frozen at -80°C until tested. 65 66 Hospitalized patient samples 67

Following informed consent under IRB protocol #823392 approved by the UPenn IRB, paired saliva and 68 combined nasopharyngeal/oropharyngeal (NP/OP) specimens (paired study test) were collected from 37 69 SARS-CoV-2 infected patients admitted to HUP's inpatient unit from July 2020 to January 2021. All 70 patients were symptomatic and had the diagnosis of COVID-19 confirmed on or before admission by PCR of a NP swab specimen; the date of this first positive test was considered as the date of diagnosis. 72

The following data were collected for each patient: age, sex, race (self-reported), date of symptom 73 onset, date of diagnosis (first positive test), date of paired study test, date of admission, date of 74 discharge, and survival status at discharge. Enrollment was limited to patients who could spontaneously 75 produce saliva (e.g.; hospitalized but non-intubated; score 4-6 on the WHO scale). 33 used to analyze the raw data and produce an overall interpretative result. assay does not have a nucleic extraction or a reverse transcription step. Following pre-amplification, the 113 specimens were diluted and mixed with master mix. The specimen mix and primer mix of each N1, N2, 114

and RNase P were loaded into individual inlets on an integrated fluid circuit (IFC) chip. The IFC chip was 115 loaded onto Juno or IFC Controller RXand then placed onto the Biomark HD (Fluidigm Corporation) 116

where the assay detects SARS-CoV-2 by RT-PCR amplification. Advanta Dx SARS-CoV-2 EUA Interpretive 117

Software was used to analyze and to produce an overall interpretative result based on Ct values and 118 reproducible replicates. Inconclusive results were excluded from the study as each inconclusive is 119 defined differently by each methodology and not directly comparable (i.e. loading error vs 1/3 targets 120 detected). Samples were run according to the Fluidigm EUA except for the use of liquid handlers to 121 automate technically challenging and time-consuming steps. Liquid handlers (Perkin-Elmer, Waltham, 122 MA) were utilized for specimen aliquoting, pre-amplification plate set-up, diluting pre-amplified 123 material, and integrated fluid chip (IFC) loading. Protocols for the liquid handlers were customized by 124

PerkinElmer following the Advanta Dx SARS-CoV-2 RT-PCR Assay EUA IFU. Assay volumes were modified 125 to accommodate dead volume for the liquid handlers, but ratios were not changed. 126

Ct values were obtainable from all testing platforms except the ePlex SARS-CoV-2 Test. Ct values 128 between the assays are not directly comparable due to inherent differences in the assay designs. The 129

Abbott RealTime SARS-CoV-2 assay detects two targets on the N gene with the same fluorophore, thus 130 inflating the single Ct value reported by this assay. The remaining assays results a single Ct value for 131 each target. A pre-amplification in the Fluidigm Advanta Dx SARS-CoV-2 RT-PCR Assay results in lower Ct 132 values than standard RT-PCR without pre-amplification. Therefore, Ct values were used to identify 133 samples near an assay's LOD or cut-off, but not for direct comparison between assays. The LOD and cut-134 off for each assay was either stated in the EUA or an approximate number based on correspondence with vendor of assay, as these exact values are often obtained through proprietary interpretive 136 algorithms ( Table 1) December 2020. Of the 2500 pairs, approximately 150 pairs were from participants that were 155 symptomatic (~6%). The remaining pairs were from asymptomatic participants. In this study population, 156 the SARS-CoV-2 detection rate was ~1% for both AN and saliva (36/2500, 37/2500, respectively). Figure Using AN as the reference standard, the sensitivity and specificity of saliva were 86.1% (95% CI, 73.9-161 98.3) and 99.8% (95% CI, 99.6-100), respectively. Alternatively, using saliva as the reference standard, 162 the sensitivity and specificity of AN were 83.7% (95% CI, 70.8-96.8) and 99.8% (95% CI, 99.6-100), 163 respectively. The calculated sensitivity and specificity of AN and saliva show that both specimen types 164 perform similarly in detecting SARS-CoV-2. 165

The majority of AN samples (2497/2500) were run on either the Thermo TaqPath (n=1570), Abbott 166 m2000 (n=414), or Roche cobas for the 6800/8800 (n=513). Concordance, sensitivity, and specificity 167 were calculated individually to compare saliva with each assay ( Table 3) . While the overall concordance 168 and specificity was similar compared to all assays, the sensitivity of saliva varied (71.4% to 100%) 169 depending on the comparator assay. 170

The discordant samples are outlined in Table 4 produced a similar small number of likely false negatives suggesting neither specimen type to be overtly 196 better than the other. After determining the most likely resolution of these discordant samples, the 197 resolved sensitivity and specificity of saliva were 87.5% (95% CI, 76.5-98.5) and 99.9% (95% CI, 99.8-198 100), respectively, and the resolved sensitivity and specificity of AN were 90.0% (95% CI, 80.2-99.8) and 199 100%, respectively. These differences in sensitivity were not statistically significant. from symptom onset to paired NP/OP-saliva testing was 9.2 days (range 1-17 days) and from diagnosis 205 (first positive NP test) to paired NP/OP-saliva testing was 4.2 days (range 0-11 days). The mean length of 206 stay in the hospital was 6.5 days (range 1-21 days) and all the patients were discharged alive ( Table 5) Discordant samples were further investigated to determine potential causes for disagreement ( Table 7) . Higher sensitivity on the order of 94-100% has been reported in saliva samples of symptomatic 292 individuals. 6, 9, 16, 18, 42 Most of these studies, however, did not assess the time from symptom onset and it 293 is possible that the subjects were in the first week of the disease when viral titers are maximal. 40 The 294 mean time of symptom onset in Vaz et al's study was 4 days (interquartile range 3-6 days), which could 295 explain the high sensitivity in that cohort. 42 Even though the sensitivity of saliva in our study (89.3%) 296 seems to be lower than in the aforementioned studies, this percentage was calculated longitudinally 297 across a wide range of days since symptom onset (1-17 days). In fact, the positivity rate in both saliva 298 and NP/OP was 100% during the first 4 days of symptom onset (Figure 3) . Even at 1-7 days (data not 299 was an apparent trend of decreasing positivity over time, the small sample size was a limiting factor to 301 detect statistically significant differences. Similar to the findings reported by Wyllie et al, there was a 302 higher percentage of saliva samples than NP/OP samples testing positive later in the disease course. 43 303

Persistence of SARS-CoV-2 in saliva can be clinically useful as patients often seek medical attention if 304 symptoms do not spontaneously resolve, at which time nasal swab testing could be negative. 305

While sensitivity and specificity are essential, other factors such as cost and logistics also play an 306 important role in choosing a SARS-CoV-2 test. An assessment of the cost, throughput, ease of use, 307 turnaround time, and human resources needed for each of the testing methods employed in this study 308 has been published previously. 3 The use of robotic liquid handlers with the Fluidigm platform shortens 309 the length of this saliva-based assay by approximately 2.5 to 3 hours and reduces technical challenges. 310

This system was used successfully in the current study to yield high throughput, affordable, and 311 relatively quick results with saliva samples while maintaining a high sensitivity. Therefore, we 312 recommend using a saliva-based high throughput assay for large scale screening. Future studies 313 comparing the performance of different saliva-based assays are needed. 314

The current study has several limitations. In the university cohort, clinical information was not recorded 315 at the time of testing, and therefore a correlation of clinical characteristics with test outcomes was not 316

performed. In addition, it is unknown whether food or fluid intake prior to testing could have affected 317 the results, since this information was also not consistently documented. In the hospital setting, the 318 sample size was relatively small, reducing statistical power. In both populations, the heterogeneity in 319 testing methodology for upper respiratory swabs and saliva precluded a direct comparison of CT values 320 between the assays. Similarly, AN samples were tested with a variety of testing platforms, further 321 complicating this comparison. Moreover, the absence of a true diagnostic gold standard hinders accurate calculation of sensitivity and specificity as evident by the variation in sensitivity between test 323 methods. 324

In conclusion, our study provides data to support the use of saliva for SARS-CoV-2 detection in both 325 symptomatic and asymptomatic populations. Our results show that saliva has an acceptable sensitivity 326 and is, at a minimum, comparable to upper respiratory swab. Saliva testing is ideal for large-scale, 327 regular screening programs where sample collection logistics and supply shortages represent a 328 significant capacity strain and in identifying SARS-CoV-2 infections in patients presenting later in the 329 clinical course. 330

We are grateful to all those who participated in sample collection and processing: collection site staff, J o u r n a l P r e -p r o o f 

Saliva as a gold-standard sample for SARS

CoV-2 detection

Evaluation of COVID-19 Testing 341 Strategies for Repopulating College and University Campuses: A Decision Tree Analysis

A PENNdemic Year in Review

Assessment of SARS-CoV-2 Screening Strategies to Permit the

Safe Reopening of College Campuses in the United States

Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva

Performance of Severe Acute Respiratory Syndrome Coronavirus 2

Real-Time RT-PCR Tests on Oral Rinses and Saliva Samples

Evaluation of Specimen Types and Saliva Stabilization Solutions for

SARS-CoV-2 Testing

Anterior Nasal and Saliva Specimens versus Health Care Worker-Collected Nasopharyngeal

Challenges in use of saliva for detection of SARS CoV-2 RNA in 390 symptomatic outpatients

Using Cepheid Xpert Xpress SARS-CoV-2

Saliva Sampling and Its Direct Lysis, an Excellent Option To Increase the Number of SARS-CoV-2

Diagnostic Tests in Settings with Supply Shortages

Clinical Evaluation of Self-Collected Saliva by 400

Quantitative Reverse Transcription-PCR (RT-qPCR), Direct RT-qPCR

Mediated Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19

Comparing Nasopharyngeal Swab and Early Morning Saliva for the Identification of Severe Acute 410

Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Non-invasive saliva 412 specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low 413 prevalence

415 Comparison of saliva and nasopharyngeal swab SARS-CoV-2 RT-qPCR testing in a community 416 setting

SARS-CoV-2: First report from India

Saliva Alternative to Upper Respiratory Swabs for

SARS-CoV-2 Diagnosis. Emerg Infect Dis 2020

Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the 426 community setting

Saliva sample as a non-invasive specimen for the diagnosis of Lung DC

Saliva RT-PCR Sensitivity Over the Course of SARS-CoV-2 Infection. JAMA 2021. 436 32. Sahajpal NS

Clinical Validation of a

Sensitive Test for Saliva Collected in Healthcare and Community Settings with Pooling Utility for

WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection: A 442 minimal common outcome measure set for COVID-19 clinical research

Methods and 445 recommendations for evaluating and reporting a new diagnostic test

The New York Times Company, 07/21/2021. p. 16. 449 36. Hassan A: Washington State Sets Vaccine Mandate for State and Health Care Workers

Saliva-based testing for diagnosis of SARS-CoV-2 458 infection: A meta-analysis

Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: a Systematic 461 Review and Meta-analysis

Relative sensitivity of anterior nares and nasopharyngeal swabs for initial 463 detection of SARS-CoV-2 in ambulatory patients: Rapid review and meta-analysis

468 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2

Hock-a-loogie saliva as a 472 diagnostic specimen for SARS-CoV-2 by a PCR-based assay: A diagnostic validity study

Workflow Integrated With Cas13a for SARS-CoV-2 Detection

SARS-CoV-2 from Saliva by Colorimetric Reverse-Transcription Loop-Mediated Isothermal

Amplification

Field-deployable, rapid diagnostic testing of saliva for SARS-CoV-2. Sci Rep 2021

Overall Concordance, % 75

Saliva Sensitivity, % Saliva Specificity